NEOG vs PACB Stock Comparison
NEOG currently leads PACB in this stock comparison, with AIQ scores of 63 vs 48. The clearest difference is risk resilience, while PACB has the stronger momentum profile.
What is the main difference between NEOG and PACB?
NEOG leads the current stock comparison as Neogen Corporation, with the clearest separation coming from risk resilience and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Neogen Corporation vs Pacific Biosciences of California, Inc.
NEOG leads
NEOG leads by 15 AIQ points, primarily on Risk Resilience and Quality, but the lead has narrowed from 22 points over 30 sessions.
Competitive: 4 of 6 evidence groups support NEOG, its lead is narrowing, and its current signal state is conflicted.
Neogen Corporation
Pacific Biosciences of California, Inc.
The Algovestiq AIQ Score currently favors NEOG over PACB, 63 versus 48 as of Nov 18, 2026. NEOG's advantage is driven primarily by stronger risk resilience and quality, while PACB holds the stronger momentum profile. NEOG also shows the weaker technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor NEOG today, and the comparison is rated Competitive on stability: the leader's advantage has been narrowing. NEOG lead: Weakening — the AIQ differential moved from 22 to 15 points over 30 sessions.
Compare Neogen Corporation and Pacific Biosciences of California, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare NEOG and PACB against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience57 vs 24NEOG +33
- Quality63 vs 32NEOG +31
- Value49 vs 23NEOG +26
- Momentum74 vs 84PACB +10
4 of 6 evidence groups favor NEOG. NEOG’s edge is concentrated in risk resilience and quality; PACB keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.
Largest factor move: Value -1
New signals
- OBV Bullish Divergence — bullish, volume, medium horizon (-4.9%)
- RSI Bullish Divergence — bullish, momentum, medium horizon
- Stochastic Oversold Bounce — bullish, momentum, short horizon
Largest factor move: Value -1, not enough on its own to move the overall score.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- Stochastic Oversold Bounce — bullish, momentum, short horizon
NEOG's lead narrowed by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — NEOG and PACB both carry a full feed there.
The central trade-off
NEOG (Neogen Corporation): the stronger current systematic profile, led by risk resilience and quality.
PACB (Pacific Biosciences of California, Inc.): the counter-case, on momentum, technicals — but at materially higher volatility, 114.1% against 40%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
NEOGNEOG on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
PACBPACB on combined revenue and EPS growth.
Value
NEOGNEOG on the peer-relative Value factor, by 26 points.
Momentum
PACBPACB on the Momentum factor, by 10 points.
Lower downside
NEOGNEOG on Risk Resilience, by 33 points.
Analyst upside
NEOGNEOG on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | NEOG | PACB | Note |
|---|---|---|---|
| Implied upside to target | +26.4% | +5.2% | NEOG has more room |
| Target dispersion | 0% | +59.7% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 4 | 8 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor NEOG. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | NEOG | 63 vs 48 |
| Fundamentals | Even | revenue growth -1.1% vs 4%; gross margin 47.4% vs 34.5% |
| Valuation | NEOG | Value 49 vs 23 |
| Technicals | PACB | Price vs 50-day -9.5% vs -8.7%; vs 200-day 6.8% vs 22.4% |
| Risk Resilience | NEOG | Risk Resilience 57 vs 24 |
| Analyst expectations | NEOG | Target upside 26.4% vs 5.2% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of NEOG and PACB and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 15 points. (supports the conclusion holding)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on NEOG.
How the comparison changed
120 daily snapshots · Jun 1 – Nov 18NEOG lead: Weakening — the AIQ differential moved from 22 to 15 points over 30 sessions.
- Today
- NEOG +15
- 63 vs 48
- 7 sessions ago
- NEOG +16
- 65 vs 49
- 30 sessions ago
- NEOG +22
- 66 vs 44
- 90 sessions ago
- NEOG +33
- 63 vs 30
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
4 bullish / 1 bearish / 1 neutral, conflicted
Only NEOG
- OBV Bullish Divergence — bullish, volume, medium horizon (-4.9%)
- RSI Bullish Divergence — bullish, momentum, medium horizon
3 bullish / 3 bearish / 1 neutral, conflicted
Only PACB
- Beta Spike Warning — bearish, risk_regime, long horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
Both carry 4 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, MACD Histogram Expanding Bearish, Stochastic Oversold Bounce.
NEOG leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +1.65%, AIQ -1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.55%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1PACB closes the Risk Resilience gap — currently 33 points behind, the largest single contributor to NEOG's edge.
- 2PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3NEOG's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 7 points over 30 sessions, and a further 15-point move would eliminate NEOG's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | NEOG | PACB |
|---|---|---|
| Revenue growth (YoY) | -1.1% | 4% |
| EPS growth (YoY) | 0% | 14.3% |
| Gross margin | 47.4% | 34.5% |
| Operating margin | -0.8% | -99.6% |
| Return on equity (TTM) | -0.6% | 61.7% |
| Debt to equity | 0.37 | -11.49 |
Performance
Split across windows| Metric | NEOG | PACB |
|---|---|---|
| 1 week (5 sessions) | -4.5% | -13.1% |
| 1 month (20 sessions) | -4.9% | 13.3% |
| 3 months (63 sessions) | -5.4% | 62% |
| 6 months (126 sessions) | 37.1% | 75% |
| Year to date | 60.7% | 4.8% |
| 1 year (252 sessions) | 73.6% | 12.6% |
Technicals
PACB has the stronger structure| Metric | NEOG | PACB |
|---|---|---|
| RSI (14) | 40.1 | 43.1 |
| ADX (14) | 13.4 | 27.4 |
| Price vs 50-day | -9.5% | -8.7% |
| Price vs 200-day | 6.8% | 22.4% |
| Volatility (1M, annualized) | 40% | 114.1% |
Risk
NEOG is the more resilient| Metric | NEOG | PACB |
|---|---|---|
| Beta | 1.41 | 2.1 |
| Sharpe ratio | 1.19 | 0.61 |
| Sortino ratio | 2.24 | 0.96 |
| Max drawdown | -27.7% | -58.4% |
| Current drawdown | -19.7% | -32.4% |
| Annualized volatility | 57.9% | 93.5% |
| Value at risk (95%) | -4.4% | -9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, NEOG or PACB?
On the Algovestiq AIQ Score, NEOG is the stronger of the two as of Nov 18, 2026, scoring 63 against PACB's 48. The edge comes from risk resilience and quality. PACB is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is NEOG or PACB the better buy right now?
NEOG carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor NEOG over PACB?
The composite weights Quality, Value, Momentum and Risk Resilience. NEOG leads Risk Resilience by 33 points; NEOG leads Quality by 31 points; NEOG leads Value by 26 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, NEOG or PACB?
Analyst price targets imply +26.4% upside for NEOG and +5.2% for PACB, so the Street currently favors NEOG. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, NEOG or PACB?
NEOG is the better-valued of the two on the peer-relative Value factor. NEOG on the peer-relative Value factor, by 26 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, NEOG or PACB?
PACB on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, NEOG or PACB?
PACB on the Momentum factor, by 10 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, NEOG or PACB?
NEOG is the more resilient of the two, so the other name carries the higher downside risk. NEOG on Risk Resilience, by 33 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is NEOG more profitable than PACB?
NEOG leads on the comparable margin measures — gross margin 47.4% vs 34.5%; operating margin -0.8% vs -99.6%; ttm roe -0.6% vs 61.7%.
Is NEOG's lead over PACB getting stronger or weaker?
NEOG lead: Weakening — the AIQ differential moved from 22 to 15 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.
What would change the NEOG vs PACB verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PACB closes the Risk Resilience gap — currently 33 points behind, the largest single contributor to NEOG's edge; PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; NEOG's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 7 points over 30 sessions, and a further 15-point move would eliminate NEOG's advantage entirely.
What do the current signals say about NEOG and PACB?
NEOG: 4 bullish / 1 bearish / 1 neutral, conflicted. PACB: 3 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on NEOG is Golden Cross Active (bullish, long horizon). On PACB it is Golden Cross Active (bullish, long horizon).
Compare NEOG and PACB with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.